Umesh Kathad

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 10

Top Topics

Papillary Thyroid

Top Venues

Cancer research communications

Clinical cancer research : an official journal of the American Association for Cancer Research

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Aditya Kulkarni, Jianli Zhou, Neha Biyani, Umesh Kathad, Partha P Banerjee, Shiv Srivastava, Zsombor Prucsi, Kamil Solarczyk, Kishor Bhatia, Reginald B Ewesuedo, Panna Sharma
LP-184, a novel acylfulvene molecule, exhibits anti-cancer activity against diverse solid tumors with homologous recombination deficiency. Cancer research communications (2024)
Aditya Kulkarni, Jianli Zhou, Neha Biyani, Umesh Kathad, Partha P Banerjee, Shiv Srivastava, Zsombor Prucsi, Kamil Solarczyk, Kishor Bhatia, Reginald B Ewesuedo, Panna Sharma
LP-184, a Novel Acylfulvene Molecule, Exhibits Anticancer Activity against Diverse Solid Tumors with Homologous Recombination Deficiency. Cancer research communications 4 (5) (2024)
Aditya Kulkarni, Jianli Zhou, Neha Biyani, Umesh Kathad, Partha P Banerjee, Shiv Srivastava, Zsombor Prucsi, Kamil Solarczyk, Kishor Bhatia, Reginald B Ewesuedo, Panna Sharma
LP-184, a novel acylfulvene molecule, exhibits anti-cancer activity against diverse solid tumors with homologous recombination deficiency. Cancer research communications (2024)
Aditya Kulkarni, Jianli Zhou, Neha Biyani, Umesh Kathad, Partha P Banerjee, Shiv Srivastava, Zsombor Prucsi, Kamil Solarczyk, Kishor Bhatia, Reginald B Ewesuedo, Panna Sharma
LP-184, a Novel Acylfulvene Molecule, Exhibits Anticancer Activity against Diverse Solid Tumors with Homologous Recombination Deficiency. Cancer research communications 4 (5) (2024)
Aditya Kulkarni, Jianli Zhou, Neha Biyani, Umesh Kathad, Partha P Banerjee, Shiv Srivastava, Zsombor Prucsi, Kamil Solarczyk, Kishor Bhatia, Reginald B Ewesuedo, Panna Sharma
LP-184, a Novel Acylfulvene Molecule, Exhibits Anticancer Activity against Diverse Solid Tumors with Homologous Recombination Deficiency. Cancer research communications 4 (5) (2024)
Aditya Kulkarni, Jianli Zhou, Neha Biyani, Umesh Kathad, Partha P Banerjee, Shiv Srivastava, Zsombor Prucsi, Kamil Solarczyk, Kishor Bhatia, Reginald B Ewesuedo, Panna Sharma
LP-184, a novel acylfulvene molecule, exhibits anti-cancer activity against diverse solid tumors with homologous recombination deficiency. Cancer research communications (2024)
Umesh Kathad, Neha Biyani, Raniero L Peru Y Colón De Portugal, Jianli Zhou, Harry Kochat, Kishor Bhatia
Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis. PloS one 19 (8) (2024)
Umesh Kathad, Neha Biyani, Raniero L Peru Y Colón De Portugal, Jianli Zhou, Harry Kochat, Kishor Bhatia
Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis. PloS one 19 (8) (2024)
Bachchu Lal, Aditya Kulkarni, Joseph R McDermott, Rana Rais, Jesse Alt, Ying Wu, Hernando Lopez-Bertoni, Sophie Sall, Umesh Kathad, Jianli Zhou, Barbara S Slusher, Kishor Bhatia, John Laterra
Preclinical efficacy of LP-184, a tumor site activated synthetic lethal therapeutic, in glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Diana Restifo, Joseph R McDermott, Dusica Cvetkovic, Troy Dos Santos, Charline Ogier, Aizhan Surumbayeva, Elizabeth A Handorf, Caleb Schimke, C-M Charlie Ma, Kathy Q Cai, Anthony J Olszanski, Umesh Kathad, Kishor Bhatia, Panna Sharma, Aditya Kulkarni, Igor Astsaturov
Conditional dependency of LP-184 on prostaglandin reductase 1 is synthetic lethal in pancreatic cancers with DNA damage repair deficiencies. Molecular cancer therapeutics (2023)